Squarepoint Ops LLC Fate Therapeutics Inc Transaction History

Squarepoint Ops LLC

$99.2 Billion
Q4 2024

A detailed history of Squarepoint Ops LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 34,295 shares of FATE stock, worth $38,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,295

Previous 13,490 154.23%

Holding current value

$38,410

Previous $47,000 19.15%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.35 $33,496 - $69,696	20,805 Added 154.23%	34,295 $56,000
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $359,639 - $642,048	-115,269 Reduced 89.52%	13,490 $47,000
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $419,754 - $911,613	128,759 New	128,759 $422,000
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $185,255 - $442,367	112,276 Added 174.83%	176,495 $660,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $285,600 - $395,400	-60,000 Reduced 48.3%	64,219 $305,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $2 Million - $5.24 Million	-471,016 Reduced 79.13%	124,219 $708,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $5.87 Million - $14.2 Million	595,235 New	595,235 $6.01 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $234,820 - $559,844	13,207 New	13,207 $327,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $763,676 - $1.55 Million	-25,739 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $3.45 Million - $4.64 Million	-72,135 Reduced 73.7%	25,739 $1.51 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $5.42 Million - $8.75 Million	91,416 Added 1415.55%	97,874 $5.8 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $592,539 - $815,193	-8,811 Reduced 57.71%	6,458 $560,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $1.1 Million - $1.79 Million	15,269 New	15,269 $1.26 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $478,143 - $1.27 Million	-12,553 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $1.64 Million - $2.19 Million	-54,026 Reduced 81.15%	12,553 $502,000
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $1.07 Million - $1.87 Million	52,979 Added 389.55%	66,579 $2.28 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $869,201 - $1.6 Million	-50,301 Reduced 78.72%	13,600 $302,000
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $1.39 Million - $2.15 Million	-103,510 Reduced 61.83%	63,901 $1.25 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $2.06 Million - $3 Million	133,153 Added 388.68%	167,411 $2.6 Million
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $772,929 - $1.01 Million	-49,515 Reduced 59.11%	34,258 $695,000
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $842,625 - $1.2 Million	64,078 Added 325.35%	83,773 $1.47 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $411,408 - $608,512	-35,837 Reduced 64.53%	19,695 $253,000
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $485,905 - $904,616	55,532 New	55,532 $905,000
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $71,801 - $156,936	-11,397 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $44,904 - $75,676	11,397	11,397 $70,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $109M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Fate Therapeutics Inc Transaction History